Loading...
01/11 11:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
Total company revenue $1.281 billion, reflecting year-over-year growth of 6%. Revenue growth was across all segments, with currency being a tailwind of approximately $19 million.
Vision Care revenue $736 million, increased by 6% year-over-year. Growth driven by consumer and contact lenses, despite a destocking impact of approximately $6 million.
Consumer business growth 6% in Q3. Eye vitamins grew by 11%, LUMIFY generated $48 million in revenue (up 2%), and the consumer dry eye portfolio delivered $113 million in revenue (up 18%).
Contact lens revenue Grew by 6%. Daily SiHy was up 24%, Biotrue up 7%, and Ultra up 4%. U.S. market grew by 9%, and international market grew by 4%.
Surgical segment revenue $215 million, an increase of 1%. Excluding the enVista recall, revenue growth was 7%. Implantables were up 2% and 14% sequentially, consumables were flat on a constant currency basis, and equipment was up 4%.
Pharma segment revenue $330 million, an increase of 7%. U.S. branded Rx business was up 13%. Miebo delivered $84 million in revenue (71% increase year-over-year), and Xiidra delivered $87 million in revenue (TRx growth of 8%).
Adjusted gross margin 61.7%, representing a 130 basis points decrease year-over-year, mainly driven by product mix and the onetime impact of the enVista recall.
Adjusted R&D investment $95 million in Q3, representing an increase of approximately 13% over Q3 of 2024.
Adjusted EBITDA $243 million, up 7% year-over-year on a reported basis. Adjusted EBITDA margin was 19%, representing a sequential increase of 400 basis points.
Adjusted cash flow from operations $161 million in Q3, and adjusted free cash flow was $87 million.
Miebo Revenue: Generated $84 million in Q3, bolstering the dry eye portfolio.
enVista Intraocular Lenses: Achieved 27% constant currency revenue growth in premium IOLs.
Pipeline Products: Includes new formulations of LUMIFY, PreserVision, and Blink Triple Care, next-gen lifitegrast for dry eye disease, ocular surface pain medication, glaucoma medication, and a bioactive contact lens.
Daily SiHy Contact Lenses: Expanded portfolio with 24% constant currency revenue growth in Q3.
Daily SiHy Portfolio Expansion: Launched a toric model in Japan, now in over 50 countries.
Artelac Expansion: Available in more than 40 countries with plans for further expansion.
Revenue Growth: Total company revenue grew 6% year-over-year to $1.281 billion in Q3.
Adjusted EBITDA: Increased 7% year-over-year to $243 million in Q3.
Cash Flow: Adjusted cash flow from operations was $161 million in Q3.
Margin Expansion: Adjusted EBITDA margin increased by 400 basis points sequentially to 19%.
Financial Excellence: Introduced as a new category to deliver sustained profitable growth.
Innovation Focus: Pipeline filled with disruptive products aimed at elevating eye health standards.
Destocking Impact: The company absorbed a destocking impact of approximately $6 million in Q3, which could indicate challenges in inventory management or demand forecasting.
Adjusted Gross Margin Decline: Adjusted gross margin for Q3 decreased by 130 basis points year-over-year, driven by product mix and the onetime impact of the enVista recall, which could affect profitability.
EnVista Recall: The enVista recall has impacted revenue growth in the Surgical segment, although recovery efforts are underway. This poses a risk to regaining full market momentum.
Tariff Policy Uncertainty: The fluidity of tariff policies could impact the company's cost structure and profitability, although current guidance assumes the impact will be offset.
Competitive Pressures in Dry Eye Treatment: The entry of a new competitor in the dry eye disease treatment market could challenge the growth trajectory of key products like Miebo and Xiidra.
Inventory Work-Down in Consumer Segment: A work-down of inventory in the consumer segment could indicate potential challenges in demand or supply chain management.
R&D Investment Increase: The company invested $95 million in adjusted R&D in Q3, a 13% increase year-over-year, which could strain short-term financials despite its long-term potential.
Revenue Guidance for 2025: Maintaining full-year revenue guidance at a range of $5.05 billion to $5.15 billion, representing constant currency growth of approximately 5% to 7%.
Adjusted EBITDA Guidance for 2025: Updated to a range of $870 million to $910 million, raising the lower end of the range due to strong business performance.
Adjusted Gross Margin: Expected to be approximately 61.5% for the full year.
R&D Investments: Expected to be approximately 7.5% of revenue for the full year.
Interest Expense: Expected to be approximately $375 million for the full year.
Adjusted Tax Rate: Expected to be approximately 15% for the full year.
Capital Expenditures: Expected to be approximately $295 million for the full year.
Tariff Impact: Assumes the impact of tariffs in 2025 will be offset based on current policy and actions.
Pipeline and Product Launches: Anticipated launches of clinical-stage programs over the next several years, including new formulations of LUMIFY, PreserVision, and Blink Triple Care, next-generation lifitegrast for dry eye disease, ocular surface pain medication, glaucoma medication, and a bioactive contact lens.
Daily SiHy Portfolio Expansion: Continued expansion with new offerings under development, including a cost-competitive daily disposable, a frequent replacement offering, and a lens designed to slow myopia progression in children and adolescents.
PreserVision New Formulation: Expected to be on shelves in the first half of 2026, potentially increasing the addressable market for age-related macular degeneration.
EnVista IOL Platform Recovery: Faster-than-expected recovery with total enVista sales in Q3 reaching 82% of pre-recall levels and Envy sales at 91%.
The selected topic was not discussed during the call.
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
The earnings call highlights strong growth in key areas like MIEBO and contact lenses, despite challenges in the generics sector. Raised guidance for 2025 and successful recall management indicate resilience. The Q&A session reinforces confidence with strategic plans and market opportunities, despite some guidance ambiguities. Overall, positive developments in innovation, market strategy, and shareholder returns suggest a favorable stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
